{"id":"gemcitabine-vinorelbine-eribulin-or-utidelone","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and DNA synthesis. Vinorelbine is a semi-synthetic vinca alkaloid that disrupts microtubule formation and mitotic spindle function. Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth. Utidelone is a novel microtubule-stabilizing agent. Together, these agents target multiple pathways of cancer cell proliferation.","oneSentence":"This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell division and promote apoptosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:01.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Gastric cancer"},{"name":"Other solid tumors (phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT07088263","phase":"PHASE3","title":"Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Breast Neoplasms","enrollment":192},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine, Vinorelbine, Eribulin, or Utidelone","genericName":"Gemcitabine, Vinorelbine, Eribulin, or Utidelone","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell division and promote apoptosis. Used for Non-small cell lung cancer, Breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}